Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Review

Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus

Erik A Korte1, Patrick M Gaffney2 and David W Powell13*

Author Affiliations

1 Department of Biochemistry and Molecular Biology, University of Louisville School of Medicine, 570 South Preston St, Baxter Research Building I, Room 204E, Louisville, KY 40202, USA

2 Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA

3 Department of Medicine, University of Louisville School of Medicine, 570 South Preston St, Baxter Research Building I, Room 204E, Louisville, KY 40202, USA

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14:204  doi:10.1186/ar3701

Published: 20 February 2012

Abstract

Systematic lupus erythematosus (SLE) is a complex disease for which molecular diagnostics are limited and pathogenesis is not clearly understood. Important information is provided in this regard by identification and characterization of more specific molecular and cellular targets in SLE immune cells and target tissue and markers of early-onset and effective response to treatment of SLE complications. In recent years, advances in proteomic technologies and applications have facilitated such discoveries. Here we provide a review of insights into SLE pathogenesis, diagnosis and treatment that have been provided by mass spectrometry-based proteomic approaches.